Tony Cates joins Cycle Group Holdings Board of Directors Tony Cates joins Cycle Group Holdings Board of Directors News, Nityr Tony Cates joins Cycle Group Holdings Board of Directors By Holly Archer|2021-10-06T10:39:32+01:00October 6th, 2021|News, Nityr| Read More
Cycle Pharmaceuticals launches SAJAZIR TM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE) Cycle Pharmaceuticals launches SAJAZIR TM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE) News, Nityr Cycle Pharmaceuticals launches SAJAZIR TM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE) By Holly Archer|2021-09-28T11:36:58+01:00September 28th, 2021|News, Nityr| Read More
Cycle Pharmaceuticals Launches Cycle Vita™, a dedicated support platform for rare disease patients Cycle Pharmaceuticals Launches Cycle Vita™, a dedicated support platform for rare disease patients News, Nityr Cycle Pharmaceuticals Launches Cycle Vita™, a dedicated support platform for rare disease patients By Holly Archer|2021-09-14T16:56:52+01:00September 10th, 2021|News, Nityr| Read More
Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors News, Nityr Dr Alejandra Bruna joins Cycle Group Holdings Board of Directors By Holly Archer|2021-05-17T18:52:30+01:00April 29th, 2021|News, Nityr| Read More
NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand News, Nityr NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New Zealand By Holly Archer|2021-05-17T18:52:30+01:00March 15th, 2021|News, Nityr| Read More
Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel News, Nityr Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in Israel By Web_Admin|2021-05-17T18:52:30+01:00October 19th, 2020|News, Nityr| Read More
Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1) Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1) News, Nityr Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1) By Holly Archer|2021-05-17T18:52:31+01:00August 5th, 2020|News, Nityr| Read More
Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia News, Nityr Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi Arabia By Holly Archer|2021-05-17T18:52:31+01:00May 13th, 2020|News, Nityr| Read More
Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology News, Nityr Cycle Pharmaceuticals and Medherant Partner to Develop Medicines using the TEPI Patch® Technology By Holly Archer|2021-05-17T18:52:31+01:00May 5th, 2020|News, Nityr| Read More
Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics News, Nityr Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics By Holly Archer|2021-05-17T18:52:31+01:00December 18th, 2019|News, Nityr| Read More
